|
Palo Alto, CA, February 7, 2005 — Telik, Inc. (Nasdaq: TELK) announced that Michael M. Wick, M.D., Ph.D., chairman and chief executive officer, will present a company update at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on Thursday, February 10, 2005 at 3:00 p.m. Eastern time (12:00 noon Pacific time) in New York City. A live webcast of the presentation will be accessible at Telik’s website, www.telik.com. An archive of the webcast will be available on the Telik website through February 17, 2005 .
Telik, Inc. of Palo Alto , CA is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA™ (TLK286), a tumor-activated small molecule product candidate that is in three Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2005 Press Releases2004
Press Releases
2003
Press ReleasesEvents |
